Introduction: 

Recently, ZMKS tumor cells targeted therapy technology summit conference was hosted in Jiuhua, Shanzhuang, Beijing. This seminar was chaired by the most famous cancer expert and academician Sun Yan, from Oncology Hospital of the Chinese Academy of Medical Sciences. At the conference, Luo Rongcheng, director of the cancer center of the South Hospital, explained the new technology of international targeted cancer therapy treatment. The founder of ACTL technology, Professor Liu Yong who came from Stanford University. Professor Liu introduced the new technology of ACTL tumor cells targeted therapy. More than 200 delegates from over hundred hospitals had attend. After the seminar, Professor Liu was invited to do an interview, with the treatment procedure, and application prospect of new technology of ACTL tumor cells targeted therapy.

Narration: 

Journalist：
Professor Liu，you had just introduced us this newly developed technology. Could you also tell us what type of patients are suitable or not suitable for this treatment?

Liu:
This treatment is focused on those solid tumors, tumors in the head and neck , esophageal cancer, gastric cancer, colon cancer, bile duct cancer, lung cancer, ovarian tumors and breast cancer. Generally as long as certain antigen index of the tumor cells is positive, they are suitable for such treatment. The patients who are not suitable for this treatment are most likely those patients whose immune system is already is malfunction, or those who have taken some toxicitic drugs which suppressing the function of bone marrow and destroying the immune system. The rest of the patients are suitable for this kind of treatment after the further diagnoses .

Journalist：
What is the treatment process for the patient?

Liu:
The treatment process for the patient goes like this:
The doctor should first diagnosis that such patient is acceptable for the treatment by extracting venous blood 50-100 ML. These blood cells will be cultured in an advanced sterile laboratories for 14 days. He can then start receiving the treatment at the hospital. The blood drawing for the second treatment would be carried out before the reinjection of the first treatment, then another 14 days cultivation. It also means that and each month can carry two treatments. Each complete course is 3 months-long treatment, i.e.  six treatments is a complete course, we then review how effectiveness of the treatment on such patient. Patient may continue with the treatment, should result came out as positive. If vice versa, this treatment would be hold off. Of course, number of patients shown with positive curative effect with receiving of two months treatment, then they can continue with it.

Journalist：
How about the application prospect of this technology?

Liu:
Promising. Because in the European and American countries, this technology develops by leaps and bounds. Targeted cells treatment has become the main treatment method these days. There are number of Chinese scientists anticipating that such treatment shall become the main force of cancer treatment in a few years.